Lanean...
Profile of sacubitril/valsartan in the treatment of heart failure: patient selection and perspectives
With an estimated prevalence of 5.8 million in the USA and over 23 million people worldwide, heart failure (HF) is growing in epidemic proportions. Despite the use of guideline-directed medical therapies such as angiotensin-converting enzyme inhibitors, beta-adrenergic blockers, angiotensin receptor...
Gorde:
| Argitaratua izan da: | Vasc Health Risk Manag |
|---|---|
| Egile Nagusiak: | , , , |
| Formatua: | Artigo |
| Hizkuntza: | Inglês |
| Argitaratua: |
Dove Medical Press
2017
|
| Gaiak: | |
| Sarrera elektronikoa: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5634378/ https://ncbi.nlm.nih.gov/pubmed/29042791 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/VHRM.S114784 |
| Etiketak: |
Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!
|